<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="558">
  <stage>Registered</stage>
  <submitdate>12/09/2005</submitdate>
  <approvaldate>16/09/2005</approvaldate>
  <actrnumber>ACTRN12605000423617</actrnumber>
  <trial_identification>
    <studytitle>Phase I trial of the safety and the effect on immune parameters of an immunotherapy for glioma based on cultured autologous dendritic cells presenting autologous tumour cell antigens derived from irradiated glioma cells</studytitle>
    <scientifictitle>Phase I trial of the safety and the effect on immune parameters of an immunotherapy for glioma based on cultured autologous dendritic cells presenting autologous tumour cell antigens derived from irradiated glioma cells</scientifictitle>
    <utrn />
    <trialacronym>RMQ0331</trialacronym>
    <secondaryid>Queensland Institute of Medical Research (QIMR): QIMR P570</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Glioblastoma</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Brain</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Autologous dendritic cell vaccine using autologous irradiated cells as antigen source administered at 2 weekly intervals for the first 6 injections, then 6 weekly thereafter, for 1 year or until disease progression.</interventions>
    <comparator>No comparator (phase 1, single arm study)</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Safety</outcome>
      <timepoint>After each vaccine (fortnightly for 6 injections, then 6 weekly for 1 year.) Evaluations will also be performed within 6 weeks of the final vaccination and whenever clinically indicatedor until disease progression).  Final analysis will occur by 14 months after the last patient entered into the study had their first vaccination.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Clinical efficacy based on the time interval between the first vaccination and disease progression.</outcome>
      <timepoint>Disease progression is assessed at vaccination (fortnightly for 6 injections, then 6 weekly for 1 year, within 6 weeks of the final vaccination and whenever clinically indicated.  Final analysis will occur by 14 months after the last patient entered into the study had their first vaccination.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Confirmed Malignant Glioma, Macroscopic tumour resection, normal haematolological parameters, acceptable liver and renal function parameters.</inclusivecriteria>
    <inclusiveminage>1</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Extensive intracranial disease precluding total or subtotal resection, ECOG status &gt;2, History of autoimmune disease or immunosuppressive therapy, Prior use of immunotherapeutic agent, Positive serology for HIV, Hep B or Hep C, Significant non-malignant disease, Pregnancy, Other malignancy, Patients in whom only biopsy or partial resection was possible.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate>30/06/2003</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>10</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Government body</primarysponsortype>
    <primarysponsorname>Queensland Institute of Medical Research (QIMR)</primarysponsorname>
    <primarysponsoraddress>300 Herston Rd, Herston Brisbane 4006</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>The Sylvia and Charles Viertel Charitable Foundation</fundingname>
      <fundingaddress>ANZ Trustees LTD, 100 Queen St Melbourne 3000</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Royal Brisbane and Womens' Hospital Research Foundation</fundingname>
      <fundingaddress>Block 20, Butterfield St, Herston 4006</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>Not applicable</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>QIMR</ethicname>
      <ethicaddress>Herston, QLD 4006</ethicaddress>
      <ethicapprovaldate>11/07/2003</ethicapprovaldate>
      <hrec>EC00278</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Brisbane and Womens' Hospital</ethicname>
      <ethicaddress>Herston, QLD 4029</ethicaddress>
      <ethicapprovaldate>16/06/2003</ethicapprovaldate>
      <hrec>EC00172</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Mater Misericordiae Hospital</ethicname>
      <ethicaddress>South Brisbane, QLD 4101</ethicaddress>
      <ethicapprovaldate>12/08/2003</ethicapprovaldate>
      <hrec>EC00332</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Chris Schmidt</name>
      <address>Queensland Institute of Medical Research
300 Herston Road
Herston QLD 4006</address>
      <phone>+61 7 33620313</phone>
      <fax>+61 7 38453510</fax>
      <email>Chris.Schmidt@qimr.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr David Walker</name>
      <address>Department of Neurosurgery
Royal Brisbane and Womens' Hospital
Brisbane QLD 4029</address>
      <phone>+61 7 36367470</phone>
      <fax>+61 7 36362632</fax>
      <email>David_Walker@health.qld.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Agnieszka Mitchell</name>
      <address>Queensland Institute of Medical Research, 300 Herston Rd Herston Brisbane 4006</address>
      <phone>07 3362 0241</phone>
      <fax>07 3362 0109</fax>
      <email>Agnieszka.Mitchell@qimr.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>